PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Compliance Implementation Services

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

New Hire Brings Extensive Pharmaceutical Government Programs Expertise - Compliance Implementation Services (CIS), a pharmaceutical compliance consulting firm is pleased to announce the addition of new management team member, Bill Baxter
New Hire Brings Extensive Pharmaceutical Government Programs Expertise

 

NewswireToday - /newswire/ - Philadelphia, PA, United States, 2009/03/30 - Compliance Implementation Services (CIS), a pharmaceutical compliance consulting firm is pleased to announce the addition of new management team member, Bill Baxter.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

CIS is excited to have Mr. Baxter, a proven professional who will help guide the company’s continued growth, specifically in the Government Programs area.

Bill Baxter has over 38 years diverse pharmaceutical industry experience including Medicaid Contracting, Government Affairs, Sales, Sales Management, and Training. Prior to his work at Johnson & Johnson, he taught social studies in the St. Louis School System.

“Many in the industry know Bill’s work with the numerous federal and state programs and his vast experience and knowledge in the Medicaid market,” said Chris Cobourn, VP Regulatory Compliance and Practice Lead.

“His expertise will be a valuable asset to CIS. This is especially true now with so many changes and increased scrutiny at both the Federal and State levels. Bill has been involved in Medicaid and other programs since their beginning. His well rounded understanding of the programs, including the agencies, the regulations, and the operational and organizational impact at the manufacturer, brings a unique perspective that will be a great compliment to our current staff of GP consultants, and we are very excited to have him join the CIS family.”

Bill formerly held the position of Chairman of State Health Care Policy Council, an organization tasked with providing a forum for J&J operating company management to review emerging health care issues and developing policy. He was also a participating member of J&J Medicaid and Medicare Task Forces.

About CIS
CIS (cis-partners.com) is a pharmaceutical compliance consulting firm specializing in establishing a "Culture of Compliance" by providing a deep understanding of industry laws and regulations, innovative and practical approaches and fit-for-purpose solutions. CIS consultants understand and specialize in interpreting and implementing legal and regulatory requirements that have the greatest impact on research, development and commercial activities. This allows clients to proactively manage risk through identification and integration of appropriate compliance strategies.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Compliance Implementation Services

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


New Hire Brings Extensive Pharmaceutical Government Programs Expertise

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Jackie O'Connor 
484-445-7200 jacquelineoconnor[.]cis-partners.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Compliance Implementation Services securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Compliance Implementation Services / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

U.S. FDA Approves New Indication for Ipsen’s Somatuline® Depot (lanreotide) Injection for the Treatment of Carcinoid Syndrome
Genentech Provides Update on First Lampalizumab Phase III Study for Geographic Atrophy, an Advanced Form of Age-Related Macular Degeneration
mProve Health and Greenphire Partner to Deliver a First-of-its-Kind Patient Engagement Solution
FDA Approves Genentech’s Actemra (Tocilizumab) for the Treatment of CAR T Cell-Induced Cytokine Release Syndrome
Greenphire Named to Inc. 5000 for Fifth Consecutive Year
Five Community Health Centers Honored for Innovative Approaches to Medication Therapy Management
FDA Grants Priority Review for Genentech’s Gazyva in Previously Untreated Follicular Lymphoma
ProSci Incorporates Flow Cytometry Screening to Custom Monoclonal Antibody Service
FDA Grants Priority Review to Genentech's Emicizumab for Hemophilia A with Inhibitors
BD Expands Suite of Blood Culture Offerings with New BD BACTEC™ Standard Aerobic & Standard Anaerobic Plastic Bottles
Twist Bioscience Collaborates with Synbio Technologies to Supply Long DNA to Customers
FDA Grants Priority Review and Breakthrough Therapy Designation for Zelboraf (vemurafenib) in Erdheim-Chester Disease with BRAF V600 Mutation
Ipsen Receives Positive CHMP Opinion for Approval of Xermelo® (telotristat Ethyl)
BD Receives FDA 510(k) Clearance for New Immunological Diagnostic System
Positive Phase III Results for Genentech’s Emicizumab in Hemophilia A Published in The New England Journal of Medicine

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  RightITnow Ltd

Visit  NAKIVO, Inc.





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)